In particular 68 Gallium DOTATATE, which has a predominant affinity for somatostatin receptors type 2 (SSTR2), can dramatically improve the spatial resolution and lesion detectability compared to octreoscan, MIBG scintigraphy, and F-FDGPET/CT in neuroendocrine tumours and non-GEP-NETs tumours, being mostly accurate in staging patients in whom metastatic cancers spread, particularly to the bone is suspected [16, 17]. The gene discussed is SSTR2; the disease is metastatic malignant neoplasm.